A Clinical Comparison in Finland of Two Oral Contraceptives Containing 0.150 mg Desogestrel in Combination with 0.020 mg Or 0.030 mg Ethinylestradiol

References

• Jick H, Dinan B, Rothman K J. Oral contraceptives and nonfatal myocardial infarction. JAMA 1978; 239: 1403–6
   PubMed Web of Science ®Google Scholar
• Maguire M G., Tomascia I, Sartwell P E., Stolley P D., Tookman M S. Increase risk of thrombosis due to oral contraceptives. Am J Epidemiol 1979; 110: 188–95
   PubMed Web of Science ®Google Scholar
• Stadel B V. Oral contraceptives and cardiovascular disease (first of two parts). New Engl J Med 1981; 305: 612–8
   PubMed Web of Science ®Google Scholar
• Mammen E F. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142: 781–90
   PubMed Web of Science ®Google Scholar
• Stolley P D., Tonascia J A., Tockman M S., Sartwell P E., Rutledge A H., Jacobs M P. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197–208
   PubMed Web of Science ®Google Scholar
• Meade T W., Greenberg G, Thompson S G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-microgram oestrogen preparations. Br Med J 1980; 280: 1157–61
   PubMed Web of Science ®Google Scholar
• Stadel B V. Oral contraceptives and cardiovascular disease (second of two parts). New Engl J Med 1981; 305: 672–7
   PubMed Web of Science ®Google Scholar
• Midgley A R., Jaffe R. Human luteinizing hormone in serum during the menstrual cycle: determination by radioimmunoassay. J Clin Endocrinol 1966; 26: 1375–81
   Google Scholar
• Michael G. Hormone assays and the gynaecologist. Fertil Steril 1976; 27: 229–37
   Google Scholar
• Jaffe B, Behrman H R. Methods of hormone radioimmunoassay. Academic Press, New York 1974; 347
   Google Scholar
• Punnonen R, Nummi S, Ylikorkala O, Alapiessa U, Karvonen P, Viinikka L. A composite picture of the normal menstrual cycle. Acta Obstet Gynecol Scand (Suppl) 1975; 51: 63–70
   Google Scholar
• Bergink E W., Hamburger A D., de Jager E, van der Vies J. Binding of a contraceptive progestogen Org 2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J Steroid Biochem 1981; 14: 175–83
   PubMedGoogle Scholar
• Bergink E W., Borglin N E., Klottrup P, Liukko P. Effects of desogestrel and levonorgestrel in low-dose estrogen oral contraceptives on serum lipoproteins. Contraception 1982; 25: 477–85
   Google Scholar
• Cullberg G, Samsioe G, Andersen R F., et al. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicenter study on a triphasic and a fixed dose combination. Contraception 1982; 26: 229–43
   PubMed Web of Science ®Google Scholar
• Cullberg G, Dovre P A., Lindstedt G, Steffensen K. On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand (Suppl) 1982; 111: 47–54
   Google Scholar
• Samsioe G. Study on effect of 30 μg ethinylestradiol (EE) + 150 μg desogestrel on lipid and lipoprotein metabolism in healthy volunteers, also in comparison with 30 μ EE +150 μg levonorgestrel. Acta Obstet Gynecol Scand (Suppl) 1982; 111: 55–60
   Google Scholar
• Bergink E W., van Meel F, Turpijn E W., van der Vies J. Binding of progestagens to receptor proteins in human MCF-7 cells. J Steroid Biochem 1983; 19: 1563–70
   PubMedGoogle Scholar
• Bergink E W., Bos E S., Kloosterboer H J., Lund L, Nummi S, van der Vies J. Oral contraceptives and lipoproteins, P A. van Keep, H Kopera. International Health Foundation, Brussels 1983; 52–63
   Google Scholar
• Weijers M J. Development of an oral contraceptive containing a new progestogen, desogestrel, and 30 μg ethinylestradiol. Acta Obstet Gynecol Scand (Suppl) 1982; 111: 1–60
   Google Scholar
• Deville J L., Gaspard U S., Dubois M. Clinical evaluation of 600 cycles under triphasic oral contraception. New considerations in oral contraception, I Brosens. Biomed Information Corp, New York 1982; 223–33
   Google Scholar
• Allen H. Multicenter clinical evaluation of oral triphasic contraceptives in Canada. New Considerations in oral contraception, I Brosens. Biomed Information Corp, New York 1982; 223–33
   Google Scholar